Screener
CorMedix CRMD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: CorMedix’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001410098-26-000021
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Foreign exchange effect on cash | - | - |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 33,250 | 25,635 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH - BEGINNING OF PERIOD | 145,825 | 40,756 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH - END OF PERIOD | $179,075 | $66,391 |
| Cash paid for interest | $2,817 | $10 |
| Supplemental Disclosure of Non-Cash investing and financing Activities: | ||
| Additional capital expenditures included in accrued expenses and other liabilities | $97 | - |
| Disposal of ROU assets and liabilities for finance lease | $(53) | - |
Item 1. Unaudited Condensed Consolidated Financial Statements.
FAQ
- What is CorMedix's cash & equivalents?
- CorMedix (CRMD) reported cash & equivalents of $179.08M in Q1 2026.
- How has CorMedix's cash & equivalents changed year-over-year?
- CorMedix's cash & equivalents increased by 169.7% year-over-year, from $66.39M to $179.08M.
- What is the long-term trend for CorMedix's cash & equivalents?
- Over 5 years (2020 to 2025), CorMedix's cash & equivalents has grown at a 28.2% compound annual growth rate (CAGR), from $42.1M to $145.83M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about CorMedix's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude